Management Team
Gilbert Gonzales, MD
Founder, Chief Executive Officer
Dr Gonzales is a serial entrepreneur, neurologist, and inventor. Gilbert founded/co-founded Prism Pharma, Clear Vascular, NeuroSn, Inc., Serene, LLC and Exubrion Therapeutics, Inc. Author of of Sn-117m publications and patents.
Nigel Stevenson, PhD
Chief Scientific Officer
Dr Stevenson is a serial entrepreneur, internationally recognized nuclear physicist, and inventor. He is the former Group Leader of Isotope Production Head of Applied Technology at TRIUMF, and has organized/chaired numerous national and international conferences and scientific meetings related to isotopes. Prior to Serene, Nigel was a founder/member of senior management of TcNET, LLC, Trace Life Sciences, Theragenics, and was the Chief Science Advisor of Advanced Medica
Advisors and Consultants
Philip Cohen, MD
Dr Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr Cohan has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear edicin
H William Strauss, MD
Dr. Strauss is an Attending Physician Emeritus at Memorial Sloan Kettering Cancer Center, and Professor of Radiology at Cornell University’s Weill School of Medicine. Some of his previous positions include Chief of Nuclear Medicine and Professor of Radiology at Stanford University School of Medicine, Chief of Nuclear Medicine at the Massachusetts General Hospital, and Professor of Radiology at Harvard Medical School. He also served as Vice-President of Diagnostics Drug Discovery at Bristol-Myer
Jaime Simón, Ph.D.
Dr. Simón is a co-founder of IsoTherapeutics. He is a radiochemist by training and spent 25 years at The Dow Chemical Company where he was responsible for a group dedicated to developing new pharmaceutical technologies. He holds over 50 US patents, including the key patents covering Quadramet® (153Sm-EDTMP) for the treatment of bone cancer and STR (166Ho-DOTMP) for safely ablating bone marrow prior to bone marrow transplants. Dr Simón has over 70 publications.